



# **FORTIS HEALTHCARE LIMITED**

**EARNINGS PRESENTATION – Q4 FY26 and FY26**

---

May 22, 2026

# DISCLAIMER

This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company.

Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction.

Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction.


This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this presentation, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

# About Fortis Healthcare



Note: ^Including ~1,200 O&M beds  
# Including trainee nurses



**36 Healthcare Facilities**



**~6,100 Operational Beds<sup>^</sup>**



**~7,900 Doctors**



**~9,300 Nurses<sup>#</sup>**



**28,000+ employees  
(including Agilus)**



**4 JCI Accredited**



**34 NABH Accredited/  
Certified**

# AGENDA

1. Performance Highlights
  - Earnings and Financial Summary – Q4FY26 and FY26
2. Performance Review - Hospital Business
  - Beds Expansion Update
  - ESG Highlights
3. Performance Review - Diagnostics Business
4. Clinical Excellence at Fortis
5. Appendix







**Q4FY26 and FY26**  
**PERFORMANCE HIGHLIGHTS**

# BUSINESS PERFORMANCE

## Consolidated (INR Cr)



## Hospital Business (INR Cr)



# Q4FY26 SNAPSHOT

Consolidated Revenue

**2,365 Crores**

 17.8%

Consolidated Op EBITDA

**531 Crores**  
(22.5% Margin)

 22.2%

Consolidated PBT<sup>1</sup>

**337 Crores**

 16.1%

Consolidated PAT<sup>1</sup>

**284 Crores**

 17.4%

Net Debt / (Cash)<sup>3</sup>

**2,334 Crores**

Net Debt to EBITDA<sup>2,3</sup>

**1.09x vs 0.93x**

1. Excluding exceptional items

2. Basis Q4 annualized EBITDA; 3. Net Debt as on 31<sup>st</sup> Mar 2026

# FY26 SNAPSHOT

Consolidated Revenue

**9,128 Crores**

 17.3%

Consolidated Op EBITDA

**2,085 Crores**  
(22.8% Margin)

 31.3%

Consolidated PBT<sup>1</sup>

**1,388 Crores**

 26.6%

Consolidated PAT<sup>1</sup>

**1,086 Crores**

 20.9%

Net Debt / (Cash)<sup>3</sup>

**2,334 Crores**

Net Debt to EBITDA<sup>2,3</sup>

**1.09x vs 0.93x**

Board recommends dividend of INR 1 per share (10% of face value); subject to shareholders' approval

1. Excluding exceptional items

2. Basis Q4 annualized EBITDA; 3. Net Debt as on 31<sup>st</sup> Mar 2026

# Key Updates – FY26

## Acquisition of People Tree Hospital, Bengaluru

**Jan'26:** Fortis acquired the 125-bedded People Tree Hospital in Yeshwanthpur, Bengaluru, for INR 430 Cr through a 100% acquisition of TMI Healthcare Pvt. Ltd., along with the underlying land and building and an adjacent land parcel, enabling future expansion to over 300 beds.

## Long-Term Lease for 200-Bedded Greater Noida Hospital

**Sep'25:** Fortis signed a 15-year lease agreement with RR Lifesciences for a ~200-bedded multi-specialty hospital in Greater Noida, previously managed under an O&M arrangement, with expansion potential to ~250 beds.

## Acquisition of Shrimann Hospital, Punjab

**Jul'25:** Fortis consummated the acquisition of Shrimann Hospital in Jalandhar, Punjab, adding 228 beds to its network and strengthening its presence in the state from ~800 beds to ~1,000 beds.

## Launch of 'Adayu', a Dedicated Mental Health Care Facility

**Nov'25:** Fortis launched 'Adayu', a 36-bedded specialised mental health care facility located in Gurugram, offering evidence-based treatments through a multidisciplinary approach to deliver comprehensive and world-class care.

## O&M Agreement for 550-Bedded Greenfield Hospital in Lucknow

**Aug'25:** Fortis entered into collaboration agreement for Operations and Management of 550 bedded greenfield hospital to be constructed in Lucknow by the Ekana Group.

## O&M Agreement with Gleneagles

**Jul'25:** Fortis signed an Operations and Maintenance Services agreement with GHIPL, enabling Fortis to manage ~700 beds across five hospitals within the Gleneagles network.

# Q4FY26 SNAPSHOT

- Hospital business revenues grew 19.0% to INR 2,023 Cr versus INR 1,701 Cr in Q4FY25
- Hospital Business Operating EBITDA stood at INR 446 Cr, up 19.9%; while operating margin was at 22.1% versus 21.9% in Q4FY25
- Q4FY26 hospital business ARPOB was at INR 2.56 Cr per annum vs INR 2.51 Cr in Q4FY25, up 2.0%
- Occupancy for the quarter stood at 68% versus 69% in Q4FY25
- The company's diagnostics business reported gross revenues of INR 387 Cr versus INR 348 Cr in Q4FY25
- Operating EBITDA Margin of the diagnostics business (basis gross revenues) stood at 22.0% versus 18.0% in Q4FY25




# FY26 SNAPSHOT

---


- Hospital business revenue at INR 7,773 Cr versus INR 6,528 Cr in FY25, a growth of 19.1%
- Hospital business Operating EBITDA at INR 1,724 Cr versus INR 1,339 Cr in FY25, a growth of 28.7%; Margin at 22.2% vs 20.5% in FY25
- FY26 hospital business ARPOB at INR 2.51 Cr vs INR 2.42 Cr in FY25, up 3.4%
- Occupancy for the year stood at 68% in FY26 versus 69% in FY25
- Diagnostic business gross revenues were at INR 1,527 Cr versus INR 1,407 Cr in FY25
- Diagnostic Operating EBITDA Margin (basis gross revenues) for the year stood at 23.6% versus 17.7% in FY25

# CONSOLIDATED EARNINGS SUMMARY – Q4FY26


All figures in INR Cr




Up 17.8%



Up 22.2%



Up 16.1%



Up 17.4%


\* Q4FY26 PAT excludes exceptional loss of INR 12.5 Cr which pertains primarily to the impairment of investment in an associate Company

\* Q3FY26 PAT excludes exceptional net loss of INR 55.2 Cr which pertains to one-time impact of new Labour Codes set off by reversal of impairment in an associate Company of INR 9.4 Cr, resulting in net impact of INR 45.9 Cr


\* Q4FY25 PAT excludes exceptional loss of INR 53.6 Cr which pertains primarily to the impairment of investment in an associate Company and impairment of assets in a subsidiary Company

# CONSOLIDATED EARNINGS SUMMARY – FY26


All figures in INR Cr.




Up 17.3%



Up 31.3%



Up 26.6%





Up 20.9%

\* FY26 PAT excludes exceptional net loss of INR 55.2 Cr which pertains to one-time impact of new Labour Codes set off primarily by reversal of impairment in an associate Company of INR 33.0 Cr, resulting in net impact of INR 22.2 Cr

\* FY25 PAT excludes exceptional net loss of INR 89.3 Cr primarily pertaining to the impairment of investment in an associate Company and impairment of assets in a subsidiary Company, offset by gain related to the divestment of the Richmond Road, Bangalore facility

# CONSOLIDATED EARNINGS SUMMARY

All figures in INR Cr





# Q4FY26

## HOSPITAL BUSINESS HIGHLIGHTS

- Occupancy was at 68%, compared to 69% in Q4FY25. Occupied beds increased to 3,339 compared to 2,855 in Q4FY25, a growth of 17.0%.
- Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 18.1% and contributed 62% to overall hospital business revenues, similar to Q4FY25.
- Revenues from digital channels viz website, mobile application and digital campaigns witnessed a 19.0% YoY growth; contributed 29.2% to overall hospital revenues, similar to Q4FY25.
- Company further strengthened its medical talent with the onboarding of specialists in the areas of Orthopedics, Cardiac Sciences, Obstetrics & Gynecology, Neurosciences and Gastroenterology.

### Key Performance Indicators



Up 2.0%





# FY26

## HOSPITAL BUSINESS HIGHLIGHTS

- Occupancy was at 68%, compared to 69% in FY25. Occupied beds increased to 3,270 compared to 2,838 in FY25, a growth of 15.2%.
- Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 18.9% and contributed 62% to overall hospital business revenues, similar to FY25.
- International Patient revenues grew 18.5% to INR 639 Cr in FY26 vs INR 539 Cr in FY25. The business contributed 7.8% to overall hospital business revenues, similar to FY25.
- Revenues from digital channels viz website, mobile application and digital campaigns witnessed a 18.8% YoY growth; contributed 29.5%, similar to FY25.
- Key procedure volumes performed across Radiation Therapy and Robotic Surgeries increased by 19% and 66% YoY.


### Key Performance Indicators



# Q4FY26

## DIAGNOSTIC BUSINESS HIGHLIGHTS

- Agilus reported gross revenue of INR 387 Cr in Q4FY26 as compared to INR 348 Cr in Q4FY25, a growth of 11%.
- Operating EBITDA stood at INR 85 Cr in Q4FY26 versus INR 63 Cr in Q4FY25.
- Operating EBITDA Margin (basis gross revenues) stood at 22.0% versus 18.0% in Q4FY25. Excluding one offs\*, the Operating EBITDA Margin stood at 20.1% for Q4FY26 compared to 23.4% in Q4FY25.




\* In Q4FY26, one off impact on revenue and EBITDA pertains primarily to brand fee provision written back; In Q4FY25, one off expenses pertain primarily to rebranding expenses and a contingent consideration payment for an earlier lab acquisition

# FY26

## DIAGNOSTIC BUSINESS HIGHLIGHTS

- Agilus reported gross revenue of INR 1,527 Cr in FY26 as compared to INR 1,407 Cr in FY25, a growth of 9%.
- Operating EBITDA stood at INR 360 Cr in FY26 versus INR 249 Cr in FY25.
- Operating EBITDA Margin (basis gross revenues) stood at 23.6% in FY26 versus 17.7% in FY25. Excluding one offs\*, the Operating EBITDA Margin stood at 23.2% in FY26 compared to 22.0% in FY25.



\* In FY26, one off impact on revenue and EBITDA pertains primarily to brand fee provision written back; In FY25, one off expenses pertain primarily to rebranding expenses and a contingent consideration payment for an earlier lab acquisition

# OPERATING PERFORMANCE

## HOSPITAL BUSINESS

Particulars (INR Cr)	Hospital Business				
	Q4FY25	Q3FY26	Q4FY26	FY25	FY26
<b>Operating Revenue</b>	<b>1,701</b>	<b>1,938</b>	<b>2,023</b>	<b>6,528</b>	<b>7,773</b>
Revenue Growth vs LY	14.2%	19.4%	19.0%	14.8%	19.1%
<b>Reported EBITDA</b>	<b>384</b>	<b>424</b>	<b>446</b>	<b>1,388</b>	<b>1,768</b>
EBITDA growth vs LY	13.2%	24.8%	16.1%	27.3%	27.3%
<b>Margin</b>	<b>22.6%</b>	<b>21.9%</b>	<b>22.0%</b>	<b>21.3%</b>	<b>22.7%</b>
Adj: Other Income <sup>^</sup>	12	4	(0)	49	44
<b>Operating EBITDA</b>	<b>372</b>	<b>420</b>	<b>446</b>	<b>1,339</b>	<b>1,724</b>
<b>Margin</b>	<b>21.9%</b>	<b>21.7%</b>	<b>22.1%</b>	<b>20.5%</b>	<b>22.2%</b>

- Above financials includes financials of International entities which are part of Fortis group; mainly RHTTM
- <sup>^</sup> Hospital business reported EBITDA for FY26 includes other income primarily pertaining to interest income, dividend income from the Company's majority owned subsidiary Agilus Diagnostics and interest on tax refund
- <sup>^</sup> Hospital business reported EBITDA for FY25 includes other income primarily pertaining to gain on sale of assets, interest on tax refund, interest income and dividend income received from the Company's majority owned subsidiary Agilus Diagnostics;

# OPERATING PERFORMANCE

## DIAGNOSTIC BUSINESS

Particulars (INR Cr)	Diagnostic Business				
	Q4FY25	Q3FY26	Q4FY26	FY25	FY26
<b>Operating Revenue</b>	<b>348</b>	<b>371</b>	<b>387</b>	<b>1,407</b>	<b>1,527</b>
Revenue Growth vs LY	3.0%	8.3%	11.1%	2.5%	8.5%
<b>Reported EBITDA</b>	<b>71</b>	<b>92</b>	<b>97</b>	<b>274</b>	<b>393</b>
EBITDA growth vs LY	37.9%	64.2%	35.7%	19.8%	43.5%
<b>Margin</b>	<b>20.4%</b>	<b>24.9%</b>	<b>24.9%</b>	<b>19.5%</b>	<b>25.8%</b>
Adj: Other Income incl FX	9	7	11	26	34
<b>Operating EBITDA</b>	<b>63</b>	<b>86</b>	<b>85</b>	<b>249</b>	<b>360</b>
<b>Margin</b>	<b>18.0%</b>	<b>23.1%</b>	<b>22.0%</b>	<b>17.7%</b>	<b>23.6%</b>
Adj: One off impact*	19	-	(9)	61	(8)
<b>Operating EBITDA before one off exp</b>	<b>82</b>	<b>86</b>	<b>76</b>	<b>309</b>	<b>352</b>
<b>Margin</b>	<b>23.4%</b>	<b>23.1%</b>	<b>20.1%</b>	<b>22.0%</b>	<b>23.2%</b>

- \* In Q4FY25 and FY25, one off expenses pertain primarily to rebranding expenses and a contingent consideration payment for an earlier lab acquisition;
- \* For Q4FY26 and FY26, one off impact on revenue pertain primarily to brand fee provision written back and hence the same has been adjusted from revenue and EBITDA translating into margins of 20.1% in Q4FY26 and 23.2% in FY26.
- Diagnostics business revenue is on Gross Basis; Diagnostic business Q4FY26 net revenue (net of inter company elimination) stood at INR 341 Cr versus INR 306 Cr in Q4FY25 and INR 327 Cr in Q3FY26.

# BALANCE SHEET (CONSOLIDATED)

March 31, 2026

Balance Sheet (INR Cr)	Mar 31, 2025	Dec 31, 2025	Mar 31, 2026
Shareholder's Equity	9,169	9,895	10,168
Debt	2,196	2,924	2,872
Lease Liabilities (Ind AS 116)*	280	575	600
<b>Total Capital Employed</b>	<b>11,645</b>	<b>13,394</b>	<b>13,640</b>
Net Fixed Assets (including intangibles & CWIP)	6,636	7,639	7,944
Goodwill	4,194	4,468	4,722
Investments	169	229	225
Cash and Cash Equivalents	502	377	538
Net Other Assets	144	681	212
<b>Total Assets</b>	<b>11,645</b>	<b>13,394</b>	<b>13,640</b>
Net Debt / (cash)	1,694	2,547	2,334
<b>Net Debt to Equity</b>	<b>0.18x</b>	<b>0.26x</b>	<b>0.23x</b>

- *\*Pertains to lease liability on account of adoption of new accounting standard on leases w.e.f. April 1, 2019*
- *Net Debt excludes lease liabilities*
- *Net Debt to EBITDA was at 1.09x vs 0.93x for Q4FY26 and Q4FY25 (basis annualized EBITDA of Q4FY26 and Q4FY25, respectively)*




# PERFORMANCE REVIEW


HOSPITALS BUSINESS

# SPECIALTY MIX

FY25




FY26




Specialties such as Renal Sciences and Orthopedics witnessed Y-o-Y revenue growth of 22% and 21%, respectively

# PAYOR MIX

FY25





FY26





# HOSPITAL BUSINESS PERFORMANCE – Q4FY26 & FY26

Key healthcare facilities continue to witness a YoY and QoQ upward momentum in revenues



# HOSPITAL BUSINESS PERFORMANCE – FY26



Note: In FY26, FMRI, Shalimar Bagh, Noida, BG Road, Anandpur and Faridabad increased their operational beds by ~20, ~30, ~65, ~15, ~25 and ~40 beds respectively

# HOSPITAL MARGIN MATRIX

FY26

EBITDA	No of Facilities	Revenue Contribution	Operational beds	ARPOB (INR Cr)	Occupancy
>20%	13	76.2%	3,238	2.66	72%
15% - 20%	4	11.6%	559	2.52	69%
10% - 15%	1	2.2%	119	2.21	67%
<10%	6 <sup>^</sup>	8.8%	875	1.62	52%

<sup>^</sup> Note: <10% EBITDA Margin facilities include Yeshwanthpur (acquired in Jan'26), Manesar (commissioned in Sep'24) and the recently added Greater Noida facility on lease (commissioned in Oct'22)

FY25\*

EBITDA	No of Facilities	Revenue Contribution	Operational beds	ARPOB (INR Cr)	Occupancy
>20%	10	73.2%	2,611	2.67	72%
15% - 20%	5	9.2%	523	1.64	74%
10% - 15%	2	10.0%	429	2.35	69%
<10%	4	6.3%	533	1.67	50%

Note: \*FY25 numbers exclude Richmond Road facility, Bangalore (Divested in Dec'24)

Note: The margin matrix for FY25 and FY26 reflects EBITDA margins basis IND AS accounting for lease facilities




# **BEDS EXPANSION UPDATE**

---

# Beds Expansion Plan

Planned capacity addition of ~1,800 beds from FY27 to FY30 (excluding any future inorganic growth opportunities)



Note: The chart shows total capacity addition in each year – ramp up of operational beds will be done as per the business growth and occupancy trends  
 ^ 678 O&M beds added in FY26 for Gleneagles India adjusted for 155 beds of Greater Noida which was converted to lease arrangement from O&M earlier

The slide features a background with a blurred image of a person in a suit pointing upwards. Overlaid on this are several upward-pointing arrows in various colors (pink, green, blue, and olive) and a large white arrow pointing towards the top right. The text 'ESG HIGHLIGHTS' is centered in a bold green font with a green underline.

## **ESG HIGHLIGHTS**

# ESG HIGHLIGHTS



## Environment Stewardship



### Energy

Improved per occupied bed energy consumption in FY26 by **another 3.68% YoY**, cumulating to **13.1% improvement in last 3 years**



### Water

STP eject water is being **recycled for gardening, cooling towers & flushing** at 58 sites, **saving 2.75 Lakh KL** of fresh raw water in FY26




### Waste

Compostable plastics bags are being used at all units for general waste – reducing plastic pollution by **104.2 MT per year**



## Social Impact Leadership



### Sourcing from MSME/ Small producers

Direct sourcing from MSME/ Small producers has improved to **46.99% in FY26**, from **37.93% in FY25**



### Nation Building

Direct sourcing from within India improved to **99.64% in FY26**, up from **98.76% in FY25**



### Gender Diversity

**54.62%** of permanent employees at Fortis are **women**. Consistently high gender diversity across years



## Systemic Governance




### Inflation Rate Control

CAUTI infection rate has improved from **0.18 per thousand catheter days in FY25** to **0.16 in FY26**



### NPS (patient satisfaction)

Net Promoter Score (NPS) scores have **improved from 67% to 72% for OP** and **from 70% to 73% for IP patients**



### Robust Patient Feedback Management System

**Ticket based complaint resolution mechanism** for prompt resolution & closure



### Framework to report violations

**Alternative and anonymous method of reporting** suspected compliance violations, unlawful or unethical behavior



### Grievance Redressal Mechanism

Whatsapp-based grievance redressal mechanism. **All complaints closed with RCA and CAPA**



### Zero Data Breaches

We clocked **ZERO data breaches** in FY26 – ensured by robust IT systems at Fortis Healthcare



# PERFORMANCE REVIEW



---

DIAGNOSTICS BUSINESS

# DIAGNOSTICS BUSINESS – Q4FY26

## Q4FY26

- During Q4FY26, Agilus conducted 10.06 Mn tests, versus 9.59 Mn in Q4FY25.
- Agilus added 125+ Customer touchpoints\* to its network in Q4FY26.
- Agilus' B2C: B2B revenue mix stood at 53:47 in Q4FY26 compared to 51:49 in Q4FY25.





\*Note: Gross additions

# DIAGNOSTICS BUSINESS – FY26

## FY26

- During FY26, Agilus conducted 40.8 Mn tests, versus 39.2 Mn in FY25.
- Agilus added 675+ Customer touchpoints\* to its network in FY26. Total CTPs as on 31st March 2026 stood at 4,445.
- Agilus' B2C: B2B revenue mix stood at 52:48 in FY26, similar to FY25.




\*Note: Gross additions


# YEARLY REVENUE MIX

FY26


### Geographic mix






### Product Mix



### Segment Mix



FY25





**CLINICAL EXCELLENCE**

**AT FORTIS**

---

**KEY HIGHLIGHTS**

# CLINICAL EXCELLENCE

## FY26 Performance – Key Procedures



**75,900+**

**Cardiac Procedures<sup>1</sup>**



**35,200+**

**Joint Replacements and  
Other Ortho Procedures**




**10,200+**

**Robotic Surgeries<sup>3</sup>**



**~1,100**

**Transplants<sup>2</sup>**



**~10,400**

**Neuro and Spine  
Surgeries**



**15,000+**

**Radiation Therapy  
Patients**

**Note:**

FY26 witnessed YoY growth across key procedures: Cardiac Procedures grew by 13%, Ortho Procedures by 15%, Robotic Surgeries by 66%, Radiation Therapy by 19%, and Neuro and Spine Procedures by 13%

<sup>1</sup>Cardiac Procedures include Cardiac Surgery, Angiography, Angioplasty and other Cardiology procedures

<sup>2</sup>Transplants include Kidney, Liver and Bone Marrow Transplants

<sup>3</sup>Robotic Surgeries include Cardiac, Urology, Oncology, Gynae, Ortho and General Surgery

# CLINICAL EXCELLENCE

## Q4 FY26

- **Fortis Hospital, Gurugram**, performed complex hybrid cardiac surgery, combining open bypass surgery with minimally invasive endovascular repair, on a 29-year-old suffering from a ruptured and massively dilated thoracic abdominal aorta, a condition associated with extremely high mortality
- **Fortis Escorts, Okhla Road, New Delhi**, performed a balloon aortic valvotomy, a minimally invasive procedure to open the severely narrowed valve and restore blood flow, on a critically ill premature newborn delivered at 31 weeks suffering from critical aortic stenosis, severely reduced heart function, and fluid accumulation around the heart
- **Fortis Hospital, Gurugram**, performed a rare surgery to remove a 12 kg cancerous Gastrointestinal Stromal Tumour (GIST) from the abdomen of a 67-year-old woman

## Q1–Q3 FY26

- **Fortis Hospital, Anandpur, Kolkata**, performed a complex open heart surgery, including Aortic Valve Replacement, on a 53-year-old woman with a large right atrial tumour and a Sinus of Valsalva aneurysm
- **Fortis Hospital, Manesar**, performed a rare five-hour minimally invasive endoscopic cardiac surgery on a 16-year-old boy with a 35 mm atrial septal defect and other heart complications
- **Fortis Escorts, Okhla Road, New Delhi**, performed India's first combined robot assisted heart bypass (CABG) and breast cancer surgery (modified radical mastectomy) in a single 11-hour operative procedure on a 72-year-old patient



# AUGMENTING MEDICAL PROGRAMS

During the year, the Company augmented its medical infrastructure by commissioning several high-end equipment including:

- Second Da Vinci Xi Robotic Surgical System at **Fortis Hospitals in Gurugram, Mohali, BG Road** and first one at **Fortis Hospital, Manesar**
- SSI Mantra Robotic Surgery System at **Fortis Hospital, Ludhiana**
- Ortho Robotic System at **Fortis Hospitals in Nagarbhavi and Mulund**
- Cath labs at **Fortis Hospitals in Faridabad, Shalimar Bagh, Noida and Mohali**
- MRI at **Fortis Hospital in Ludhiana and Vashi**
- PET CT at **Fortis Hospital in Ludhiana**



# APPENDIX

# GROUP CONSOLIDATED P&L – Q4FY26

Particulars ( INR Cr)	Q4FY25	Q3FY26	Q4FY26
<b>Revenue from operations</b>	<b>2,007.2</b>	<b>2,265.0</b>	<b>2,364.7</b>
Other income	19.8	8.3	4.4
<b>Total income</b>	<b>2,027.0</b>	<b>2,273.3</b>	<b>2,369.1</b>
Expenses	1,571.7	1,759.4	1,832.3
<b>EBITDA*</b>	<b>455.3</b>	<b>513.9</b>	<b>536.7</b>
<b>Margin</b>	<b>22.7%</b>	<b>22.7%</b>	<b>22.7%</b>
Finance costs	67.6	85.7	84.3
Depreciation and amortisation expense	102.2	120.1	122.0
<b>PBT</b>	<b>285.5</b>	<b>308.1</b>	<b>330.5</b>
Share of profit / (loss) of associates and joint ventures (net)	4.6	3.5	6.2
<b>Net profit / (loss) before exceptional items and tax</b>	<b>290.1</b>	<b>311.6</b>	<b>336.7</b>
Exceptional gain/loss**	-53.6	-45.9	-12.5
<b>Profit / (loss) before tax from continuing operations</b>	<b>236.6</b>	<b>265.7</b>	<b>324.2</b>
Tax expense / (credit)	48.5	68.3	53.0
<b>Net profit / (loss) for the period from continuing operations</b>	<b>188.0</b>	<b>197.4</b>	<b>271.2</b>
<b>Profit / (loss) from continuing operations attributable to Owners of the company</b>	<b>183.9</b>	<b>193.7</b>	<b>265.8</b>

\* EBITDA includes other income, forex and exceptional/non-recurring expenses

\*\* Q4FY26 exceptional loss of INR 12.5 Cr pertains primarily to the impairment of investment in an associate Company

\*\* Q3Y26 exceptional loss of INR 55.2 Cr pertains to one-time impact of new Labour Codes set off by reversal of impairment in an associate Company of INR 9.4 Cr, resulting in net impact of INR 45.9 Cr

\*\* Q4FY25 exceptional loss pertains primarily to the impairment of investment in an associate Company and impairment of assets in a subsidiary Company

# GROUP CONSOLIDATED P&L – FY26

Particulars (INR Cr)	FY25	FY26
<b>Revenue from operations</b>	<b>7,782.8</b>	<b>9,127.8</b>
Other income	66.9	50.7
<b>Total income</b>	<b>7,849.7</b>	<b>9,178.5</b>
Expenses	6,194.8	7,042.9
<b>EBITDA*</b>	<b>1,654.9</b>	<b>2,135.6</b>
<b>Margin</b>	<b>21.3%</b>	<b>23.4%</b>
Finance costs	184.4	314.5
Depreciation and amortisation expense	385.6	449.4
<b>PBT</b>	<b>1,084.9</b>	<b>1,371.7</b>
Share of profit / (loss) of associates and joint ventures (net)	11.5	16.4
<b>Net profit / (loss) before exceptional items and tax</b>	<b>1,096.4</b>	<b>1,388.1</b>
Exceptional gain/loss**	-89.3	-22.2
<b>Profit / (loss) before tax from continuing operations</b>	<b>1,007.1</b>	<b>1,365.9</b>
Tax expense / (credit)	197.7	301.7
<b>Net profit / (loss) for the period from continuing operations</b>	<b>809.4</b>	<b>1,064.2</b>
<b>Profit / (loss) from continuing operations attributable to Owners of the company</b>	<b>774.2</b>	<b>1,041.8</b>

\* EBITDA includes other income, forex and exceptional/non-recurring expenses

\*\* FY26 exceptional net loss of INR 55.2 Cr primarily pertains to one-time impact of new Labour Codes set off primarily by reversal of impairment in an associate Company of INR 33.0 Cr, resulting in net impact of INR 22.2 Cr

\*\* FY25 exceptional net loss of INR 89.3 Cr primarily pertains to the impairment of investment in an associate Company and impairment of assets in a subsidiary Company, offset by gain related to the divestment of the Richmond Road, Bangalore facility



**THANK YOU**